Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1

Neuropeptides

Volumn 45, Issue 2, 2011, Pages 151-156

  Wang, Ji Gang ^a   Li, Ning Ning ^a   Li, Hai Na ^a   Cui, Li ^a   Wang, Peng ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Carcinoma; Immunohistochemistry; Neurotensin; Pancreatic ductal; Receptors; SR 48692

Indexed keywords

MECLINERTANT; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTORADIOGRAPHY; CANCER DIAGNOSIS; CANCER TISSUE; CARCINOMA CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PANCREAS CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MALE; NEUROTENSIN; PANCREATIC NEOPLASMS; PYRAZOLES; QUINOLINES; RECEPTORS, NEUROTENSIN;

AGOUTI PACA;

EID: 79951509391     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2011.01.002     Document Type: Article

References (42)

1. Buchegger F., Bonvin F., Kosinski M., Schaffland A.O., Prior J., Reubi J.C., Bläuenstein P., Tourwé D., García Garayoa E., Bischof Delaloye A. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J. Nucl. Med. 2003, 44:1649-1654.
2. Carraway R., Leeman S.E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 1973, 248:6854-6861.
3. Carraway R.E., Plona A.M. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides 2006, 27:2445-2460.
4. Ehlers R.A., Kim Sh., Zhang Y., Ethridge R.T., Murrilo C., Hellmich M.R., Evans D.B., Townsend C.M., Mark Evers B. Gut peptide receptor expression in human pancreatic cancers. Ann. Surg. 2000, 231:838-848.
5. Ehlers R.A., Zhang Y., Hellmich M.R., Evers B.M. Neurotensin-mediated activation of MAPK pathways and AP-1 binding in the human pancreatic cancer cell line, MIA PaCa-2. Biochem. Biophys. Res. Commun. 2000, 269:704-708.
6. Ehrenfried J.A., Zhou Z., Thompson J.C., Evers B.M. Expression of the neurotensin gene in fetal human liver and fibrolamellar carcinoma. Ann. Surg. 1994, 220:484-489. discussion 489-491.
7. Elek J., Pinzon W., Park K.H., Narayanan R. Relevant genomics of neurotensin receptor in cancer. Anticancer Res. 2000, 20:53-58.
8. Evers B.M., Zhou Z., Dohlen V., Rajaraman S., Thompson J.C., Townsend C.M. Fetal and neoplastic expression of the neurotensin gene in the human colon. Ann. Surg. 1996, 223:464-470. discussion 470-471.
9. Guha S., Rey O., Rozengurt E. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Res. 2002, 62:1632-1640.
10. Guha S., Lunn J.A., Santiskulvong C., Rozengurt E. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1. Cancer Res. 2003, 63:2379-2387.
11. Gullo L. The effect of neurotensin on pure pancreatic secretion in man. Scand. J. Gastroenterol. 1987, 22:343-348.
12. Gully D., Canton M., Boigegrain R., Jeanjean F., Molimard J.C., Poncelet M., Gueudet C., Heaulme M., Leyris R., Brouard A., et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc. Natl. Acad. Sci. USA 1993, 90:65-69.
13. Hermans E., Maloteaux J.M. Mechanisms of regulation of neurotensin receptors. Pharmacology 1998, 79:89-104.
14. Herzig M.C., Chapman W.G., Sheridan A., Rake J.B., Woynarowski J.M. Neurotensin receptor-mediated inhibition of pancreatic cancer cell growth by the neurotensin antagonist SR48692. Anticancer Res. 1999, 19:213-219.
15. Hidalgo M. Pancreatic cancer. N Engl. J. Med. 2010, 362:1605-1617.
16. Ishizuka J., Townsend C.M., Thompson J.C. Neurotensin regulates growth of human pancreatic cancer. Ann. Surg. 1993, 217:439-445.
17. Iwase K., Evers B.M., Hellmich M.R., Kim H.J., Higashide S., Gully D., Townsend C.M. Indirect inhibitory effect of a neurotensin receptor antagonist on human colon cancer (LoVo) growth. Surg. Oncol. 1996, 5:245-251.
18. Iwase K., Evers B.M., Hellmich M.R., Kim H.J., Higashide S., Gully D., Thompson J.C., Townsend C.M. Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. Cancer. 1997, 79:1787-1793.
19. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
20. Kapuscinski M., Shulkes A., Read D., Hardy K.J. Expression of neurotensin in endocrine tumors. J. Clin. Endocrinol. Metab. 1990, 70:100-106.
21. Kisfalvi K., Guha S., Rozengurt E. Neurotensin and EGF induce synergistic stimulation of DNA synthesis by increasing the duration of ERK signaling in ductal pancreatic cancer cells. J. Cell Physiol. 2005, 202:880-890.
22. Kisfalvi K., Hurd C., Guha S., Rozengurt E. Induced overexpression of protein kinase D1 stimulates mitogenic signaling in human pancreatic carcinoma PANC-1 cells. Induced overexpression of protein kinase D1 stimulates mitogenic signaling in human pancreatic carcinoma PANC-1 cells. J. Cell Physiol. 2010, 223:309-316.
23. Lee Y.C., Uttenthal L.O., Smith H.A., Bloom S.R. In vitro degradation of neurotensin in human plasma. Peptides 1986, 7:383-387.
24. Löser C., Nustede R., Becker H.J., Köhler H., Fölsch U.R. Effect of neurotensin on pancreatic growth and pancreatic polyamine metabolism in rats. Int. J. Pancreatol. 1995, 18:107-115.
25. Mazella J. Sortilin/neurotensin receptor-3: a new tool to investigate neurotensin signaling and cellular trafficking?. Cell Signal. 2001, 13:1-6.
26. Meggiato T., Ferrara C., Tessari G., Plebani M., De Paoli M., Del Favero G., Naccarato R. Serum neurotensin in human pancreatic cancer. Tumori 1996, 82:592-595.
27. Mijatovic T., Gailly P., Mathieu V., De Nève N., Yeaton P., Kiss R., Decaestecker C. Neurotensin is a versatile modulator of in vitro human pancreatic ductal adenocarcinoma cell (PDAC) migration. Cell Oncol. 2007, 29:315-326.
28. Nustede R., Schmidt W.E., Köhler H., Fölsch U.R., Schafmayer A. Role of neurotensin in the regulation of exocrine pancreatic secretion in dogs. Regul. Pept. 1993, 44:25-32.
29. Reubi J.C., Waser B., Friess H., Büchler M., Laissue J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 1998, 42:546-550.
30. Reubi J.C., Waser B., Schaer J.C., Laissue J.A. Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas. Int. J. Cancer. 1999, 82:213-218.
31. Rey O., Yuan J., Rozengurt E. Intracellular redistribution of protein kinase D2 in response to G-protein-coupled receptor agonists. Biochem. Biophys. Res. Commun. 2003, 203:817-824.
32. Ryder N.M., Guha S., Hines O.J., Reber H.A., Rozengurt E. G protein-coupled receptor signaling in human ductal pancreatic cancer cells: neurotensin responsiveness and mitogenic stimulation. Cell Physiol. 2001, 186:53-64.
33. Sakamoto T., Newman J., Fujimura M., Greeley G.H., Townsend C.M., Thompson J.C. Role of neurotensin in pancreatic secretion. Surgery 1984, 96:146-153.
34. Schotte A., Leysen J.E., Laduron P.M. Evidence for a displaceable non-specific [3H]neurotensin binding site in rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 1986, 333:400-405.
35. Smith D.M., Haggitt R.C. The prevalence and prognostic significance of argyrophil cells in colorectal carcinomas. Am. J. Surg. Pathol. 1984, 8:123-128.
36. Tanaka K., Masu M., Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron 1990, 4:847-854.
37. Townsend C.M., Bold R.J., Ishizuka J. Gastrointestinal hormones and cell proliferation. Surg. Today 1994, 24:772-777.
38. Vincent J.P., Mazella J., Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol. Sci. 1999, 20:302-309.
39. Wang L., Friess H., Zhu Z., Graber H., Zimmermann A., Korc M., Reubi J.C., Büchler M.W. Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. Clin. Cancer Res. 2000, 6:566-571.
40. Wood J.G., Hoang H.D., Bussjaeger L.J., Solomon T.E. Effect of neurotensin on pancreatic and gastric secretion and growth in rats. Pancreas 1988, 3:32-339.
41. Yamada M., Ohata H., Momose K., Yamada M., Richelson E. Pharmacological characterization of SR48692 sensitive neurotensin receptor in human pancreatic cancer cells, MIA PaCa-2. Res. Commun. Mol. Pathol. Pharmacol. 1995, 90:37-47.
42. Yuan J., Rozengurt E. PKD, PKD2, and p38 MAPK mediate Hsp27 serine-82 phosphorylation induced by neurotensin in pancreatic cancer PANC-1 cells. J. Cell Biochem. 2008, 103:648-662.